THC “without the high” could be a “game-changer”

Published: 8-Mar-2017

Newly developed compounds limit psychoactivity and cognitive impairment, especially useful for paediatrics

Vitality Biopharma has created a library of glycosides of THC (delta-9-tetrahydrocannabinol). This is the main psychoactive chemical found in cannabis or marijuana.

The library has enabled targeted delivery to reduce or eliminate psychoactivity when used in oral drug formulations.

The corporation specialises in researching and developing cannabinoids for the treatment of serious neurological and inflammatory disorders.

This new drug opens up novel opportunities for treatment of pain and inflammation.

These compounds are being developed as pharmaceuticals that enable site-specific targeting of the THC in various tissues of the body, where it can exert therapeutic effects for treatment of pain and inflammation.

In December, Vitality obtained DEA approval for its research and development facilities located in California.

The company has now completed preclinical pharmacokinetics studies with its THC glycosides to analyse their bioavailability.

We can exploit the receptor system without compromising cognitive function.

The company has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain.

This enables their formulation within pharmaceuticals where drug psychoactivity will be reduced or eliminated.

It is THC without the high and could be a game changer.

“This new drug opens up novel opportunities for treatment of pain and inflammation,” said Brandon Zipp, Director of R and D at Vitality.

“We can now exploit the cannabinoid receptor system without systemic THC that compromises cognitive function.”

Robert Brooke, CEO of Vitality, added:

“It is THC without the high and could be a game changer, especially for treatment of indications like Crohn's disease and for use in children.”

You may also like